Warfarin

Warfarin

SCHEMBL3792087

CC(=O)C[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

VKORC1

The experimentally established mechanism targets of Warfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
VKORC1 known ✓ Q9BQB6 3/20 1.00
CYP2C9 P11712 10/20 1.00
ALB P02768 2/20 1.00
HSD17B10 Q99714 2/20 1.00
KDM4E B2RXH2 1/20 1.00
ALDH1A1 P00352 1/20 1.00
PCSK7 Q16549 1/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
NR1I2 O75469 1/20 0.77
NR3C1 P04150 1/20 0.77
ADRA1A P35348 1/20 0.77
KCNH2 Q12809 1/20 0.77
CYP3A4 P08684 1/20 0.74
BRD4 O60885 1/20 0.68
NQO1 P15559 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Warfarin SCHEMBL29400364 1.00 CYP2C9 (1.00) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL3689 1.00 CYP2C9 (1.00) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL662875 1.00 CYP2C9 (1.00) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL2139452 1.00 CYP2C9 (1.00) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL4439794 1.00 CYP2C9 (1.00) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL4757598 0.99 CYP2C9 (0.97) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL34347 0.99 CYP2C9 (0.97) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL2597774 0.99 CYP2C9 (0.97) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL13278154 0.99 CYP2C9 (0.97) CYP2C9VKORC1ALBHSD17B10KDM4E
Warfarin SCHEMBL5016404 0.99 CYP2C9 (0.97) CYP2C9VKORC1ALBHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101983-A1 NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES BRANDEIS UNIVERSITY (US) 2025-05-15 WO claimed
CN-119541900-A Evaluation method for influence of traditional Chinese medicine on warfarin anticoagulation effect based on PK/PD theory 哈尔滨医科大学 2025-02-28 CN claimed
US-20240100126-A1 Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug I2O THERAPEUTICS INC (US) 2024-03-28 US claimed
WO-2022036444-A1 ATTRACTANT BLEND COMPOSITION COMPRISING 2,3,5-TRITHIAHEXANE, 1-HEXANOL AND/OR 3-METHYL-2-PENTANONE, AND DEVICES AND METHODS FOR ATTRACTING FEMALE MICE GRIES GERHARD (CA) 2022-02-24 WO claimed
EP-4682237-A2 SYSTEM FOR FUNCTIONAL TESTING AND TRANSPORTATION OF BIOLOGICALLY ENGINEERED ORGANS Miromatrix Medical Inc. (US) 2026-01-21 EP disclosed
EP-3896148-B1 SYSTEM FOR FUNCTIONAL TESTING AND TRANSPORTATION OF BIOLOGICALLY ENGINEERED ORGANS MIROMATRIX MEDICAL INC (US) 2025-12-03 EP disclosed
US-20250228236-A1 EXTRACORPOREAL ORGAN SUPPORT SYSTEM MIROMATRIX MEDICAL INC. 2025-07-17 US disclosed
EP-3443338-B1 METHODS FOR DETECTION OF SAMPLE ENANTIOMERS USING DIFFERENTIAL MOBILITY SPECTROMETRY DH TECHNOLOGIES DEV PTE LTD (SG) 2025-07-09 EP disclosed
WO-2025137586-A2 COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING PHOSPHATE SOLUBILIZATION IN PLANTS Tenfold Technologies, LLC (US) 2025-06-26 WO disclosed
WO-2025101983-A1 NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES BRANDEIS UNIVERSITY (US) 2025-05-15 WO disclosed
EP-3462875-B1 DEVICE FOR ATTRACTING A RODENT GRIES GERHARD J (CA) 2025-05-07 EP disclosed
CN-119541900-A Evaluation method for influence of traditional Chinese medicine on warfarin anticoagulation effect based on PK/PD theory 哈尔滨医科大学 2025-02-28 CN disclosed
WO-2023069939-A1 SYSTEM FOR SUPPORTING BIOLOGICALLY ENGINEERED ORGANS MIROMATRIX MEDICAL INC. (US) 2023-04-27 WO disclosed
WO-2023069930-A1 EXTRACORPOREAL ORGAN SUPPORT SYSTEM MIROMATRIX MEDICAL INC. (US) 2023-04-27 WO disclosed
US-20220233633-A1 ORAL OCTREOTIDE THERAPY AND CONTRACEPTIVE METHODS AMRYT PHARMACEUTICALS INC. 2022-07-28 US disclosed
EP-3981442-A1 MOBILE DEVICE OPERABLE BY MEANS OF A TEMPERATURE DIFFERENCE FOR CLEANING AND DISINFECTING ROOM AIR Münch, Elke (DE) 2022-04-13 EP disclosed
EP-3978038-A1 MOBILE DEVICE OPERABLE BY MEANS OF A TEMPERATURE DIFFERENCE FOR CLEANING AND DISINFECTING ROOM AIR AND TEST DEVICE FOR SAME Münch, Elke (DE) 2022-04-06 EP disclosed
US-20100273203-A1 METHODS AND COMPOSITIONS FOR DETECTING METABOLITES BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2010-10-28 US disclosed
US-5856525-A ANTICOAGULANTS; RACEMIC MIXTURE OF S AND R-WARFARIN DUPONT PHARMACEUTICALS COMPANY (US) 1999-01-05 US disclosed
US-5686631-A OXIDATION OF RACEMATE, STEREOSPECIFIC HYDROGENATION WITH CHIRAL PHOSPHINE CATALYST THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-11-11 US disclosed